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I.

INTRODUCTION

In the last decade the need to image the heart has
led to the investigation of various ions that could serve
as cardiac imaging agents in healthy and in non-functioning
cardiac tissue and provide prognostic information allowing
earlier medical or surgical intervention in patients with
acute myocardial Infarction.
These imaging agents have been found to function by
mimicking the action of the normal in vivo cations
Thallium

(ie.

K*).

(to be discussed in greater detail later) has been

shown to function as

an excellent K+ analogue in many systems

(1) and to serve as an excellent myocardial imaging agent
for the relative quantitation of infarct size

(2,3).

Gustin

(4) in 1975 felt that Cesium-129 was also an accurate myocar¬
dial imager for the localization and relative quantification
of acute myocardial infarction.

A

be

size

to

accurately

niques.

quantify

infarct

future

goal would

using

these

tech¬

To be able to use cardiac imaging in a quantitative

manner, we must understand factors affecting the uptake of
the Imaging agent thallium.
It is well established that diuretic drugs effect
tionic balance in the renal tubule

(5^6).

ca¬

Only a few studies

have shown an extrarenal site of diuretic drug action.
Sellers in 1975

(7) provided some of the earliest evidence

for diuretics exerting a direct effect on the myocardium.

He found that furosemide and ethacrynic acid individually
increased the digitalis induced myocardial loss of potassium
from the dog heart as measured by arterial-venous differences.
In addition there is evidence that ethacrynic acid and triam¬
terene act on the erythrocyte Na+,K+-ATPase as well as the
renal tubule cells.

With these leads on the extrarenal sites

of action of diuretics as well as with the many known changes
in cationic balance caused by diuretics, we felt it was
reasonable to study one of these diuretics in relation to the
myocardium in more detail.
It is the goal of this investigation to study the
potent kaliuretic diuretic,

furosemide,

in an in vivo mammal¬

ian system, to see if its acute or chronic administration
under an eukalemic or chronic hypokalemic environment,

affects

the myocardial tissue concentration and kinetics of
thallium-201 under these various conditions.

We

anticipate that

the information derived from this study may help to contri¬
bute to the understanding of the mechanisms of the interre¬
lationship between potassium dynamics,
and furosemide;

in addition,

it

may

cationic enzyme systems,

eventually

contribute to the knowledge needed for accurately sizing
myocardial infarcts with ^OLpi.

-2-
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II.

IMAGING AGENTS - THALLIUM-201

Thallium,
periodic table

a metallic element in group IIIA of the

(2), has properties that closely resemble

potassium in biologic systems,

suggesting to Kawana that

tracer quantities of 201 T1 may be

used to image the

myocardium(2).
Available evidence suggests that the movement of
thallous thallium and potassium in animals is related
Mullins and Moore

(8)

(1).

found that both the influx and efflux

patterns of thallium were very similar to potassium when
frog muscle was used as a test tissue.
in 1964

Gehring and Hammond

(9) presented evidence indicating that the mechanism

associated with the active transport of potassium into rabbit
erythrocytes also transported thallium.

All the experiments

suggested a great similarity in the ionic movements of thall¬
ium and potassium.

By determining and comparing the disap¬

pearance of 20^T1 and

from plasma and the uptake of these

ions by tissues as a function of time,

the degree to which

these ions are interchangeable was characterized(1).
concentrations of 204ip]_ an£ 42^ qn heart,
intestine,

skin, brain,

time were similar.

The

lung, muscle,

liver and spleen as a function of

The high initial concentration of these

ions in the heart and lung immediately following injection
were related to blood flow

(1).

201rp]_ concentrates in the

myocardium in relation to the distribution of
perfusion under normal flow,

and partial and total occlusion

3

-

regional

-

of the coronary artery(2).

Thallium appears to concentrate

in the myocardium to a greater degree than potassium and ru¬
bidium,

2.08

%

dose compared to 1.25

%

dose and 1.15

%

dose

respectively at 10 minutes, which is the time most commonly
employed for imaging(2).
Maximal myocardial and renal concentration occurs at
10 minutes.

The maximal total organ content of thallium in

the myocardium is
minutes.
parts:

3*7

%

of the injected dose at 10 to 25

The half life of 201f]_ j_n the myocardium is in two
4.4 hours

(78#) and 40 hours

of 201fp from the blood is

than that of

j_n

felt that since the concentra¬

the heart and lung were consistently greater
these tissues probably had a slightly

greater affinity for the 204^]^
^O^Tl and

The half life

less than one minute(lO).

Gehring and Hammond(l)
tion of ^C^Tl

(22%).

and although the uptake of

by tissues may be related,

there are sites with¬

in the cell having a greater affinity for thallium than for
potassium(1).

The kinetic analysis of simultaneous plasma

decay data for 204^ and 42^ suggested that the uptake of
these ions by tissues are similar.

An analysis of the organs

of the body suggested that handling of 204ff an(j 42^ by the
kidney,

testes and intestine was different(1).
Since the uptake of potassium is in part dependent on

an active trasport system and since the uptake of thallium
and potassium by tissue compartments is related, thallium
probably is also actively transported into cells.

4

-

-

It has

been shown in rabbit erythrocytes that the movement of
thallium into the cells results from the active transport of
thallium by a mechanism responsible for the active transport
of potassium(9).

Evidence strongly suggested that Na+,K+

activated ATPase isan essential component of the active K
transport mechanism(11).

The finding that thallium can

substitute for potassium in causing activation of this
enzyme provided further evidence that the uptake of thallium
by all cells in part occurs via the active transport system
associated with the uptake of potassium(l).

In addition,

/

Britten and Blank in 1968

(12)

found that thallium replaces

potassium in activating the Na+,K+-sensitive ATPase of rabbit
kidney with an affinity approximately ten times potassium for
the potassium activating site.

An additional property that

thallium and potassium have in common is their limiting ionic
conductances in water at 25°C

(Tl+,

74.7 and K+,

73-54),

indicating that the hydrated Tl+ is almost identical
to the hydrated K+.

in size

It is undecided whether the substitution

is by hydrated ions at the solvated site or by free ions inter¬
acting with an enzyme site.

It has also been shown that

thallium is handled like potassium by rat sartorius muscle
and also that thallium behaves like potassium during electri¬
cal excitation of that tissue.

These studies established

that thallium is a substitute for potassium in vivo(12).
Potassium-43 is not considered ideal for imaging because
of its high photon energies

(373 and 619 kev),

5
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-

short shelf

.

life

(t 1/2 = 22.4 hours),

and high cost.

Thallium-201, with

all the evidence for its functioning as an excellent analog
of potassium in vivo,

on the other hand,

is considered ideal

to use as an imager since it emits relatively low energy
gamma photons of 69-83 kev in 90% abundance plus gamma rays
of 135

(2%)

and 167

(8%) kev in 10% total abundance, giving

lower total body radiation to the patient, has a half life
of 73-5 hours, has a short time interval both between the
injection and the optimal scintiscan (10-20 minutes)

and

between the onset of infarction and scintigraDhic results
(few hours)(2,3,13)•

Its

low energy photon and X-ray emissions

make the use of high resolution low energy collimators with
either the rectilinear scanner or scintillation camera fea¬
sible to image the tracer while imaging K or Rb requires
high energy low resolution collimators(14,15,16).

Since

the low energy X-ray emission from thallium-201 are more
abundant and the resolution with the two high resolution
scintillation camera systems is satisfactory with the narrow¬
er window,
ium^).

the X-ray is the optimal method of imaging thall¬

Imaging with thallium-201 after an acute myocardial

infarct gives a dose of 3.8 rads per mCi to the kidneys of
man.

12% of administered activity is excreted with the urine

and 6% with the feces(3).
During the acute phase of a myocardial infarction, both
necrotic and ischemic tissue is demonstrated by thallium-201
since this ion concentrates in the myocardium in relation to
the distribution of regional myocardial flow.
6-

-

Subsequent

formation of collaterals in previously ischemic regions leads
to recurrence of thallium-201 uptake.

Defect size depends

on the time of the scintigraphic study after the onset of the
infarct and must be considered if quantification of infarct
size by thallium-201 is to be attempted.

Disadvantages of

thallium-201 scintigraphy are that no exact differentiation
can be made between acute infarction and ischemia and that
thallium-201 cannot distinquish between old and new infarct¬
ion.

Thallium-201 has the advantage of its use in early de¬

tection within 6 hours,

and probably within minutes,

after

the onset of symptoms(17)•
Thallium differs from potassium in that thallium is
poisonous to mammals in a dose of 20 mg per kg (2).

7
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III.

FUROSEMIDE
Furosemide is a weak anthranilic acid derivative

producing dilatation of renal vasculature and an increased
blood flow rate especially in the renal cortex and a decreased
rate in the outer medulla(18,19,20).

After oral intake the

diuretic response occurs within an hour.

Given intravenously

it occurs within 2-10 minutes with peak electrolyte response
in 30 minutes.

After intravenous administration,

some furo¬

semide is filtered at the glomerulus although more important
is secretion by the proximal tubule, both of which give a
combined excretion of two-thirds of the diuretic.

The

proximal tubule secretion is blocked by competitive inhibitors
of proximal tubule organic acid transport.
third is excreted in feces.
plasma protein 85-90/5(19).
unchanged drug following
liver,

plasma and lung.

The remaining

Furosemide is bound to dog
The highest concentration of
furosemide is found in kidney,

Heart, muscle and fat show less

radioactivity per gram of tissue than seen per ml of plasma.
Furosemide appears in urine intact

(96-99% of total urinary

radioactivity) within the first 1/2 hour after intravenous
administration.

In a 24 hour collection period,

80% of

urinary radioactivity excreted by dogs remained unchanged(19).
(Mechanisms of action to be discussed in section IV).

-

IV.

MECHANISMS OF POTENT DIURETICS WITH EMPHASIS ON
FUROSEMIDE AND POTASSIUM EXCHANGE
Many studies have shown that the active movements of

Na+ and K+ are closely linked under most conditions, since
+
inward K
transport occurs only with an outward movement of
Na

ions.

A membrane bound energy dependent ATPase

molecular weight between 300,000-400,000)

(with a

is known to mediate

the active movement of these cations through the plasma mem¬
brane of the renal tubular cell, red blood cell and myocardium
and this enzyme is stimulated synergistically by internal
Na+ ions and external K+ ions(11,20,21).

Skou in 10^0

(22)

first demonstrated that this Na+;K+-ATPase is inhibited by
ouabain.
It has been found that 3 Na ions bind on the inside
and two K Ions bind on the outside of the red blood cell mem¬
brane Na ,K -ATPase
hydrolyzed.

("pump")

for each molecule of ATP

This ATPase requires ATP hydrolysis at a rate

dependent on external K*"and internal Na+ concentrations, and
is specifically sensitive to inhibition by cardiac glycosides
unlike other ATPases which do not depend on Na1” and K*~for
their function and are probably associated with other cellular
functions.

Eoth Na ions inside and K ions outside are needed

to stimulate the pump-enzyme because these Na" and lions'
active transport in the red blood cell is coupled(21).
Levels of activity of Na+,K+-ATPase in a given tissue
correlates well with the rates of active cation transport
and pumping rate in the same tissue.

9

-

-

The specific activity

of this enzyme from red blood cells is only l/2000th of it
in kidney preparation(21).

The small distal tubular cell

mass possesses an extremely high activity of Na+,K+-ATPase
compared with other tubular structures as found by quantita¬
tive histochemical studies(20).

The highest Na+,K+-ATPase

activities were measured in the outer medulla largely made
up of the thick ascending limbs of Henle's loop(23).
Glycosides given intraarterially produce natriuresis
and reduction in renal concentrating ability with an'inhibi4

* “

tion of Na ,K -ATPase activity in the cortex and medulla of
infused kidney(23).

The rate of binding of ouabain rather

than its capacity for binding to outer red blood cell membranes Na ,K -ATPase

(and to other systems where ouabain is

effective in inhibiting this ATPase,

ie. myocardium),

is

depressed proportionally by increasing the external K+ concentration(21,24,25).

However,

this increase in K concentration

eventually alters neither the peak inotropic effects of
digoxin nor the myocardial concentration of
only slows the rates to its achievement(25).

H-digoxin;

it

In addition,

+■

K appears to decrease the rate of combination of ethacrynic
acid with this transport system(26).

There is much evidence

that when the cell gets enough digoxin to inhibit the pump
completely,

+
+
the permeation of Na and K
through the membrane

is not entirely accounted for by passive "leakages".
Ethacrynic acid partially inhibits this remaining Na+ outflux
and K

influx In digoxin treated cells through a digoxin-insen-

sitive pump

(ATPase)

called Pump II.

10
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This pump is not affected

by the external K concentration(27).
pump

The digoxin-sensitive

(ATPase) which exchanges Na+ for K+ is called Pumn 1(28).
The kinetic behavior of the active K influx in the

presence of digoxin and ethacrynic acid is consistent with a
model in which binding of K at one of the K-sensitive sites
in the transport system reduces the affinity of the system
for the ethacrynic acid and binding of a second ion further
reduces the affinity(26).

Another possibility is that digoxin

does not compete for the K+ or Na+ sites on the ATPase but
binds to an allosteric site on the cell membrane which leads
to a conformational change on the ATPase enzyme which then
inhibits its transport functions(29,30).
Furosemide,

as well as other potent diuretics, has

been found to affect cationic movement in systems other than
the renal tubule,

such as the red blood cell,

salivary duct

epithelium and the myocardium(7,31,32).
There are a number of different explanations existing,
many of which are interrelated,
natriuresis.

about how furosemide causes

Furosemide exerts its effect from the luminal

surface of the tubule(33).

Inhibition of ionic absorption

from the ascending limb of the loop of Henle is one of the
major effects of furosemide in the human kidney and this has the
effect of reducing the diluting and concentrating ability of
patients(18).

Furosemide also leads to a metabolic alkalosis

since more chloride is lost than bicarbonate,

in addition to

the increased loss of hydrogen and potassium(27).
Furosemide affects several transport processes in the

11-

-

kidney.
sodium,

It is known to cause increased urinary loss of
chloride,

calcium,

and magnesium by the same ner

cent as sodium and to a lesser extent potassium in man;
these effects are independent of glomerular filtration rate(l8).
On micro puncture and microperfusion studies on single
nephron segment,

Burg in 1973

ascending limb of Henle’s

(33)

showed that in rabbit thick

loop that the active transport of

chloride is the driving force for ionic movement and that
sodium ions passively
a concentration of 10

followed the chloride.
-5

-6

or 10

Furosemide, at

M in luminal fluid ,inhibits

this chloride transport process only in the thick ascending
limb in vitro and not elsewhere in the tubule, with a decrease
in net NaCl absorption and potential difference at the lumen
from _5 to 0.

Concentrations of furosemide as high as 10

-4

M

whether placed In the bath and/or the lumen had no definite
effect on the proximal convoluted tubules or cortical collect¬
ing tubules(33).

Natochin in 1976

(44) working with frog

skin found that furosemide decreases chloride permeability
rather than inhibiting the chloride pump as found by Burg(33)j
then leading to the inability of the cells to reabsorb the
sodium(34).
Since the thick ascending limb is the major site of
NaCl reabsorption in the distal nephron,

inhibition of its

function could lead to a greater diuresis than a comparative
inhibition limited to the proximal tubule(33).
Schmidt and Dubach in 1970
mide inhibited Na

+

(20)

reported that furose-

+
,K activated ATPase in the ascending limbs

12

-

'

-

of Henle's loop and distal tubules of rat in the same areas
where the Na

+

+
,K ATPase is found to be most abundant and most

likely mediates Na transport,

and that it was unclear if

any relation between this ATPase and the active chloride trans¬
port existed(20,33) .
Most investigators believe in a direct influence of
furosemide on cell metabolic pathways linked to cation trans¬
port by directly inhibiting renal oxidative metabolism(7,20,35,36).
In vivo and in vitro studies revealed a depressed oxygen
uptake in renal slices after 10
same extent as 10

_^

-4

M furosemide to about the

M ouabain, both being high doses.

A

competitive inhibition of energy production was noted(20).
Manuel in 1976

(36)

found that both ethacrynic acid and fur¬

osemide inhibited oxidative phosphorylation in the rat kidney
in vitro by inhibiting electron transport through phosphory¬
lation site II.

Biochemical bypass of site II significantly

alleviated the respiratory inhibition by both agents.

Both

diuretics caused a reduction of flavoproteins and an oxidation
of the cytochromes.
Kessler in 1969

(37)

demonstrated in dogs that furose¬

mide caused a natriureses of 30 to 407 of the filtered load
of sodium.

Cortical concentration of nucleotides were unaffected

whereas in the medulla,

ATP and ADP rose in a similar way as

found after ouabain application.

Thus furosemide appears

either to stimulate ADP and ATP production or, more likely,
to inhibit medullary ATP utilization.

According to Kessler,

reduction of the Na+,K+ATPase may explain these results with

13
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this ATPase also acting as the renal receptor for furosemide.
In 1956,

Glynn (38)
4

* "

movements of Na

demonstrated that the passive

*■{■

and K

ions deviated from the values expected

of independent leaks of each cation down its own electrochem¬
ical gradient.

This discrepancy has been generally attributed

to exchange diffusion (which is an equal flux of a single ion
species in both directions across the membrane mediated by
the same carrier that cannot bring about a net ion transport)
%

and there is some evidence that at least part of the ouabaininsensitive Na+ movements in red cells results from this pro¬
cess (39) •
A second possible explanation is that ouabain-insensitive fluxes of Na

+

and K

4-

are not independent but are coupled.

Several findings suggest that Na+ and K+ may be cotransported
into the red cell by the same mediated process.
influx is stimulated by the presence of K+ ions

First, Na+
in the medium

and this increment in Na+ influx is prevented by furosemide.
Similarly,

the K+ influx,

presence of ouabain,

20-25! of which persists in the

is doubled or tripled when Na+ ions

are added to the medium and this increment in K+ influx is
abolished by furosemide.

The synergism observed between the

inward movement of Na+ and K+ in the presence of ouabain
suggests that each ion facilitates the inward transport of
the other.

Moreover,

the inhibition of the K+-stimulated

+ .
+
+
Na -influx as well as the Na -stimulated K -influx by furose¬
mide indicates that these mutually stimulated cation fluxes
occur through the same pathway, which is sensitive to
furosemide(23,32,39,^0).

Since the magnitude of the furosemide sensitive influxes
of Na+ and K+ are not significantly different
ueq/ml cell/h respectively)

(0.39 and

0.12

the data are consistent with an

inwardly directed cotransport mechanism,

defined as a stoich¬

iometric coupling between the inward movement of Na+ and K+
and for which each ion is the preferred but not the obligatory
substrate.

K+ influx in the presence of ouabain does not

increase in direct proportion to the external concentration
of K+ but tends to reach a limiting value as the concentration
is increased(4l).

But in the presence of furosemide,

ouabain-insensitive K

+

the

influx shows a linear dependence of

external K+ concentration.

Thus furosemide eliminates a com¬

ponent of K+ influx that shows the saturation kinetics
typical of a facilitated diffusion process.

Omission of Na

from the medium likewise elimiates a saturable component of
K+ influx and the magnitude of the Na+ sensitive component
was nearly equal to the component inhibited by furosemide(4l,42)
Wiley

(32)

feels that one implication of this linkage

observed between inward movement of Na

+

and K

+

is that a

minimum of two transport sites are present on the outward¬
facing aspect of the furosemide-sensitive pathway.
two sites show specificity for Na

+

While these

+
and K , respectively,

it

is likely that the specificities are not absolute and that
each ion is not an obligatory cosubstrate.

Thus the furose-

+
+
mide-sensitive mechanism may transport not only Na -K
pairs
+
+
but also K -K
pairs,

if Na

with its transport site.

+

is unavailable for combination

The action of furosemide is not

15-
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confined to inhibition of cation co-transport but furosemide
also inhibits active cation fluxes by 10-15$ as measured either
by active K

influx or active Na

efflux

(32).

Cotransport mechanisms are now recognized in a variety
of tissues in which a coupled movement of Na+ ions together
with amino acids or sugar can lead to net movement of these
solutes.

Such movements can occur even against a concentra¬

tion gradient and it seems likely that the energy for uphill
solute movement is derived from the coupled movement 'of Na+
down its gradient

(43).

An analogous cotransport of Na+

plus K+ ions should likewise result in inward K+ movement
against the concentration gradient of this ion.

Thus, this

study demonstrated that furosemide inhibited the ouabaininsensitive efflux of both Na+and K+ by an action that is not
simply due to an inhibition of exchange diffusion (32).
The clinical use of furosemide during an acute myocar¬
dial infarction with pulmonary congestion is well established
in medical practice.

In an acute myocardial infarction, the

use of furosemide gives clinical relief of symptoms of pulmon¬
ary congestion frequently preceding any demonstrable diuretic
effect,
(44).

suggesting that extrarenal factors may also be Involved
These acute cardiovascular effects are due to changes

in the effective circulating volume, electrolyte alterations,
direct effects on the vascular beds and secondary reflex
effects

(34,45).

venous

capacitance rises,

at 5 minutes,

After an intravenous dose of furosemide,
limb vascular resistance declines

along with a decrease in left ventricular

16-
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.

filling pressure from about 20 to 14 mm Hg,

a decrease in

right atrial pressure and cardiac output and a decrease in
pulmonary arterial pressure due to increase in diameter or
a relaxation of the pulmonary veins all before diuresis occurs.
A redistribution in blood volume with much of it going to the
limbs seems to be important at this early stage.

Intact

renal function is not necessary for this early effect.

By

15 minutes a significant increase in glomerular filtration
rate and PAH clearance which is consistent with a rise in
renal plasma flow occurs,

and a significant diuresis begins

which further decreases the effective plasma volume.

Between

30 and 60 minutes a further reduction in left ventricular
filling pressure occurs this time due to the decrease in plasma
volume due to the brisk diuresis
Mierzwiak in 1975

(3*0

(4-4,45) -

investigated the effect of large

doses of furosemide (30 mg/kg)

on the contractility of the

heart of a vagotomized dog preparation where the blood pres¬
sure and heart rate were held constant.

He found that after

large doses of furosemide, no acute effects on the dog left
ventricle
work)

(LVEDP in cm Hn0, maximum dp/dt in mm Hg/sec,

occurred,

Therefore,

stroke

even after vagotomy and beta blockade.

any cardiovascular effects seen in man after furo¬

semide administration are most likely related to changes in
effective circulating blood volume, direct affects on vascular
beds,

electrolyte alterations and reflex effects rather than

to any direct myocardial effects(3*0.
An interesting study by Horrobin in 197(46)
that furosemide can inhibit both the potentiation and

-17-

showed

'

depressive responses that arterial and arteriolar smooth
muscles have in the presence of low (50 ng/ml)
(200 ng/ml)

and high

concentrations of prolactin, respectively, when

exposed to noradrenaline and to angiotensin.

Furosemide

returned the heart rate almost to starting values whether or
not they had been increased
or decreased

(with low concentration prolactin)

(with high concentration prolactin which is in

the range of many patients, male and female,
or congestive heart failure)

in renal failure

(56).

An important investigation closely linked to the present
investigation was

conducted by Seller in 1975

therapeutic doses of digitalis,
dog preparations,

(7).

Using

and potent diuretics in in vivo

he found that the potassium sparing diuretics,

triamterene and amiloride, reduced the digitalis-induced
increase in myocardial loss of potassium (reduced the V-A
difference), while the kaliuretic diuretics,

furosemide and

ethacrynic acid significantly increased the digitalis-induced
myocardial loss of potassium (as measured by increased V-A
difference).

This finding contradicts the previous-one by

Mierzwiak (3*0 who felt that furosemide had no direct effect
on the myocardium although Seller did not test furosemide
alone nor did he monitor cardiac contractility along with
the (V-A)r.
The finding of a cardiac effect of diuretics supports
the premise that there may be a common enzyme system respon¬
sible for K+ transport across the renal tubular membrane,
the red blood cell membrane and the myocardial membrane.

-18-
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Triamterene and amiloride block renal Na+-K+ exchange due to
a distal tubular site of action(47,48).

Triamterene also

*f*
-f*
-f*
-jstimulates both Na -K -dependent and Na -K -independent red
blood cell rr.e(T)brame ATPase

(49).

acid and possibly furosemide

In contrast,

ethacrynic

(potent diuretics due to their

renal tubular sites of action (50)), have been shown to
inhibit the digitalis-independent,Na+’K+-dependent membrane
ATPase called "Pump II"(4l,51), which has been shown to occur
in red blood cell membrane,
possible that

as previously discussed-*

It is

"PumpII" may also be present in myocardial

membrane or be one of multiple mechanisms responsible for
transporting potassium back into the myocardial cell,

one

which is digitalis-sensitive (Na+,K+-dependent ATPase)
one which is digitalis-insensitive.
similar to "Pump II".

and

The latter may be

Thus digitalis and these kaliuretic

diuretics may have additive blocking action regarding the
re-entry of potassium into the myocardial cell too (7).
Experiments combining ouabain and ethacrynic acid as
discussed earlier resulted in a complete inhibition of
fractional Na reabsorption and only a 46% inhibition of
Na

4"

4”

,K -ATPase activity.

The complete inhibition of Na reab¬

sorption at only a partial inhibition of

this ATPase is

probably caused by additional metabolic effects of ethacrynic
acid.

It was thus suggested that the Na

the only diuretic receptor (51).

+

+
,K -ATPase is not

Several natriuretic drugs

have been reported to have no influence on the Na

,K -ATPase

such as thiazides,

acetazolamide,

and xanthine

derivatives

Several investigators have attempted the

(23).

spironolactone,

unfolding of the more intimate cellular mechanisms of furosemide

-19-

and other potent diuretics

(18,31,51,52).

Another enzyme

possibly involved in the control of Na transport and water
permeability is the renal adenyl cyclase(51).

Under recent

investigation is the link between furosemide and ethacrynic
acid to cyclic
system.

3T,5T-adenosine monophosphate

(cAMP) dependent

In the Kidney adenyl cyclases with different sensi¬

tivities to hormones exist.

An ADH sensitive adenyl cyclase

is located primarily in the renal medulla and a PTH one in
the cortex.

They both increase cAMP intracellularly in the

medulla and cortex respectively.

PTH and cAMP both inhibit

phosphate reabsorption and increase calcium absorption(18,51).
ADH stimulates Na transport across the tissue by increasing
the rate of Na entry into isolated toad bladder epithelial
cells(l8).

Catecholamines can affect the kidney adenyl

cyclase system.

Beta adrenergic drugs,

such as isoproterenol,

induce an antikaliufetic effect and alpha adrenergic drugs cause
diuresis

(by inhibiting ADHaction)

all via changes in cAMP(23).

ImM furosemide and separately ImM ethacrynic acid
inhibited adenyl cyclase in homogenates of kidney cortex and
inner medulla, while amiloride did not.

In the cortex the

furosemide induced inhibition of adenyl cyclase can be
reversed by 1 U PTH and 0.1 mM isoproterenol.

Cortical PTH

normalized the inhibition of adenyl cyclase by ethacrynic
acid but the ethacrynic acid does not allow the PTH to raise
the cAMP levels as high as without the ethacrynic acid or
with furosemide.
isoproterenol.

Ethacrynic acid is not influenced by
These data indicate
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that in the cortex.

1

furosemide and ethacrynic acid may act at different sites
of the renal adenyl cyclase system.

In the inner medulla

the furosemide induced inhibition of adenyl cyclase was
partially antagonized by ADH, but 25% inhibition remained.
ADH did not reverse ethacrynic acid inhibition of adenyl
cyclase at all.

In addition,

isoproterenol was totally inef¬

fective in antagonizing the inhibition of adenyl cyclase
caused by either furosemide and/or ethacrynic acid and was
without influence on adenyl cyclase in the absence of these
diuretics.

The different action of isoproterenol on the

furosemide induced inhibtion of adenyl cyclases in the cortex
and medulla suggests that the adenyl cyclases of both kidney
zones are different.

We may be looking at a mixture of

cyclases with different sensitivities since furosemide does
not lead to a water diuresis which might be expected if it
is thought of as opposite to ADH in the adenyl cyclase system(51)Ferguson (18) believes that these results suggest that
ionic reabsorption in the kidney is controlled by a cAMP
mediated system, which is inhibited by furosemide,

since

furosemide inhibits ADH and cAMP induced Na transport but
not transport of Na in their absence in the resting condition,
and ethacrynic acid reduces Na transport in the presence of
ADH and in its absence,

although not Na transport stimulated

by cAMP (52).
Biochemical studies

show that ethacrynic acid reduces

intracellular levels of cAMP, both in the resting state and
in the presence of ADH, whereas furosemide has no effect.
However,

furosemide has chemical similarities to cAMP,
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(6X10

-4

M furosemide)

proteins

displaces cAMP from specific cAMP binding

(in both rabbit muscle and toad bladder),

inhibits

the activity of a cAMP dependent protein kinase which
phosphorylates histones in the presence of ATP, has similar
pK’s, melting points,

size and structure,

almost identical

molecular weights and at physiologic pH 7-4,
graph.

they co-chromato¬

These studies suggest that although these diuretics

are chemically different,

their similar pharmacological effects

may be explicable by a biochemical link, possibly involving
their effect on cAMP mechanisms

(18,52).

It is possible that

the diabetogenic effects sometimes seen with the clinical
use of furosemide may be due to its interference in the cAMP
systems although there is no solid evidence for this
Rupp in 197^

(53)

(52).

felt that the diuretic effect of

furosemide could be predicted from serum concentrations.
At an intravenous dose of 1 gram furosemide
concentrations close to 10

(in 40 minutes),

M were found which with 10%

protein binding was equivalent to 10

-4

M.

This concentration

gave extrarenal effects on Na transport in toad bladder,
frog skin, red blood cells,

smooth muscle cells and caused

a reversible reduction in hearing.
4 mg per minute

At an infusion rate of

(1 gram in 240 minutes)

concentration below 30 ug per ml

(10

gave a maximum serum
M with protein binding)

and at these concentrations no extrarenal effects were observed
including no reduction in hearing at this concentration (53)•
It is currently thought that potassium depletion is
a serious hazard especially in patients in chronic heart
failure since it seems to increase the risk of digoxin

22-

-

-

toxicity.
(5*0*

This depletion is usually attributed to diuretics

There have been several conflicting studies as to

whether chronic diuretic therapy actually leads to hypokalemia
and/or to the depletion of body potassium.

Since total

extracellular fluid space contains only 3% of the total
body content of potassium, plasma levels may not accurately
reflect total body or intracellular potassium status
Therefore,

several groups

(55).

(54,56) have used the technique

of measuring total body potassium (T.B.K.) by counting
radioactivity from the naturally occuring radionuclide

40

K,

the amount of which bears a constant ratio to the stable isotope

39

K which comprises the bulk of potassium.

total body monitor,

Using a

the number of counts obtained is related

to the weight of the potassium present with an accuracy by

12-556Anderson (56)
T.B.K.

in 1971 found no significant change in

in hypertensive patients treated for 8 weeks with

each of hydrochlorthiazide 50 mg twice a day and lasix 40 mg
twice a day with an intervening placebo period for 8 weeks.
However,

Dargie

(55)

found that 4 months of 40 mg

lasix per day without K supplements given to patients with
essential hypertension led to a significant decrease in T.B.K.
and in plasma K (3-9 to 3-6),

although after 12 months of this

therapy the T.B.K. was found to be normal again with the
plasma K staying at the decreased value.

In addition,

there

was a significant decrease in chloride at 4 months with no
further decrease at 12 months.
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Healy in 1970

(57) reported moderate reductions in

total exchangeable potassium (T.E.K.)
equals 9*8 grams K)

of 247 meq

in hypertensive patients after 15 weeks

treatment with 40 mg lasix twice a day.
T.E.K.

(which

This decrease in

is comparable to the reduction in mean T.B.K.

in Dargie's study at 4 months.

seen

But Dargie's group returned

to baseline at one year.

Dargie feels that this reduction

and then return in T.B.K.

may be due to a compensatory

decrease in urinary K losses despite the continuation of
other effects of furosemide,
in uric acid effect

(55),

ie.

the hypotensive and increase

since in a non-edematous patient,

K excretion can be as low as 15-30 mEq per day with furose¬
mide

(56).

He,

therefore,

concludes that there is a poor

correlation between the slightly low serum K levels and
T.B.K.
Edmonds in 1975
short action,

(58)

felt that lasix has a rapid

so that a single dose would not act over

much of the 24 hours,

allowing possible retention of K to

compensate for the excess loss.
surprised that Dargie's study
in serum K and T.B.K.

He was therefore not

(55) had only small decreases

He usually found that with thiazides,

and especially in younger patients with mild to moderate
hypertension without acid-base disturbances, that serum
K and T.B.K.

remained normal.

However, he found that some

patients did have persistent hypokalemia (less than 3.4 meq/1).
These patients tended to be older and had
hypertension.

more severe

He found that with a persistent hypokalemia.
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a 10$ decrease in T.B.K.

agreed with the two patients in

Dargie’s study with plasma potassiums of 3.2 mEq/1.
A possible mechanism for the decreaed potassium in
the sicker patients may be that cardiac failure leads to
tissue anoxia which causes the cell to be unable to accumu¬
late K which in turn leads to K depletion.
in cardiac failure,

In addition,

secondary hyperaldosteronism leads to

increased urinary excretion of potassium (55,
The final parameter of importance,
the context of this study),

58).

(especially in

to be presented here,

is hypo¬

kalemia and K depletion induced by diet.
Poole-V/ilson in 1975
each found,

(59)

and Cameron in 1975

(60)

in rabbits made chronically K deficient by a

low potassium intake for 20 days,

that there was a reduced

amount of potassium in the plasma and skeletal muscles
(quadriceps) but no change in the amount of K in the left
ventricle,

although Cameron felt that in patients in heart

failure, their myocardial potassium may be reduced.
addition,

Blushke in 1976

depleted guinea pigs
the

(6l)

In

found that in potassium-

(on a K deficient diet for 12 days),

potassium concentration in the serum and skeletal muscle

were significantly decreased by 33$ and 11$ respectively
with no decrease in K concentration in the heart muscle,
and rats on a K-deficient diet for 6-8 weeks produced a
marked reduction in the K content of the serum (from 4.9
to 1.9 meq/1) and skeletal muscle(from 460 to 304 meq/kg)
whereas K content of the heart muscle was only slightly,
but not significantly,

diminished
25
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(from 378 to 355 meq/kg).

-

Erdmann in 1971

(62)

showed in guinea pigs that K-

deficiency caused an increase in activity of the Na
activated ATPase of the heart muscle.
are supposed to inhibit the Na

-f-

-f~
,K -

Digitalis glycosides

,K -activated ATPase and

reduce the intracellular K concentration or delay the resti¬
tution of the intracellular ionic concentration.
(6l)

therefore,

Bluschke

tested whether an inhibition of the ATPase

by long term treatment

with digitoxin might change the

activity of the enzyme.

He found in guinea pigs made hypo¬

kalemia with 12 days on a K deficient diet and others treated
with 14 days of subcutaneous digitoxin
the activity of the Na
enhanced by 40$

+

(0.3 mg per kg), that

+
,K -ATPase of the heart was significantly

(compared to Erdmann’s 130$ increase)

and 30$

respectively whereas this ATPase of the kidney and brain
showed no significant change in activity compared to controls.
During this period no relationship was found between duration
of treatment and the size of the increase in activity.
“I”

As

“i"

the activity of the Na ,K -ATPase is dependent on the K con¬
centration and as cardiac glycosides are the specific inhibi¬
tors of this enzyme,

the observed increase in activity may

be explained by an adaptive response to an inhibition of the
ATPase.

The enzyme activity is expressed as a turnover of

substrate per mg total protein.

Therefore,

an increase in

activity may be caused by an enhanced turnover

(which would

mean a change of the specific properties of the enzyme)

or

by an increase in the amount of enzyme within total protein.
After kinetic studies were performed,
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it was suggested that

’

the increase in activity may possibly be caused by an increase
in the amount of enzyme as a result of an adaptive enzyme
induction(6l).
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V.

MATERIALS AND METHODS

A.

RADIONUCLIDE
The radiopharmaceutical used was cyclotron produced

ionic thallium-201 supplied as a sterile, pyrogen-free
radiochemical in 0.9% saline at pH 5-6 in a specific activity
of 1.0 mCi per ml.

Its peak energies in tissue and blood

samples were read in a well-type scintillation counter
window of 60 to 100 kev.
73-5 hours.

The half life of thallium-201 is

All samples were counted within 6 hours of

injection into the animal.

All counts were corrected to the

original time of counting of the thallium doses for the day
of the experiment.
All calculations were normalized to a 20 kg ideal
weight.
Calculation 1.

For blood samples:

CPM

X

(cc)

X (mCi injected corrected back to
injection time)

Calculation 2.

weight of animal in kg/20 kg

X

(weight of animal in kg / 20 kg )

(mCi-corrected for
time)

%

CPM / cc-mCi

For tissue concentration of thallium-201:

(CPM / g ) X (100)

=

_

X

(standard CPM / mCi)

injected dose / g
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B.

ANIMAL PROTOCOL

In all studies 15-25 kg mongrel dogs of both sexes
were anesthetized with intravenous pentobarbital
intubated with a cuffed endotracheal tube,

(25 mg/kg),

and ventilated on

room air with a Harvard respirator adjusted to the dogs’
weight.

Each dog underwent a right thoracotomy in the fourth

or fifth interspace.

The pericardium was incised and retracted.

A polyethylene catheter was placed in the left carotid artery
to monitor blood pressure,

and in the right carotid artery

for arterial blood collection,

and in the left external

jugular vein for injection of the furosemide, thallium and
saline.

A catheter was placed into the right external jugular

vein and passed into the coronary sinus under visual and
tactile observation for collection of venous blood samples.
A foley catheter was inserted for collection of urine samples
for measurement of urine volume,

electrolytes,

and for the

timing of diureses.
Simultaneous samples from the urine,

carotid artery

and coronary sinus were obtained twice during a control
period.

Carotid artery and coronary sinus blood samples

were then taken every 15 seconds for 2 minutes and every 30
seconds for the next 2 minutes after the intravenous injection
in a bolus of 1.0 mCi thallium-201 in saline into the left
external jugular vein.

After the blood was collected,

animal was sacrificed, the heart removed,

the

eight 1-2 gram

samples of free left ventricle were used for counting tissue
content of thallium-201.

Blood samples were replaced with
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equal volumes of normal saline.

Blood pressure and EKG

were monitored throughout the procedure.

All samples were

analyzed for sodium and potassium by flame photometry with
an Instrumentation Laboratories flame photometer.
The following groups of animals were studied:
1.

Control

(10 animals)

Each animal was surgically prepared and allowed to
stabilize

(blood pressure and heart rate)

for at least

30

minutes before the thallium-201 was injected.

2.

Acute lasix

(9 animals)

Each animal was surgically prepared and allowed to
stabilize as in the control.

2mg/kg furosemide was then

injected in a bolus intravenously via the left jugular vein.
At its peak effective time

(30 minutes post injection), the

uptake of potassium (thallium-201) was investigated by
injecting the bolus of 1.0 mCi of thallium-201 and collecting
the above described carotid artery and coronary sinus blood
samples,

3.

and then the ventricular tissue samples.

Chronic lasix-normal serum potassium

(7 animals)

Each animal was injected intravenously with 1-2 mg/kg
furosemide per day for 9 days with an average total dose of
10.54 mg/kg while maintained on a regular diet
Chow and water).

(Purina Dog

Venous blood samples were taken once a

week and measured for serum Na and K.

Each animal then

underwent a control procedure as above.

4.

Chronic hypokalemia-no lasix

(6 animals)

Each animal was placed on special formula Purina Dog
30
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Chow with only trace potassium.

Blood samples were drawn

once a week to determine serum potassium.

The control

procedure was carried out at least one week after the serum
potassium was found to be maintained at

5.

Chronic lasix-chronic hypokalemia

3-25 meq/1 or less.

(7 animals)

Each animal was fed the trace potassium Purina Dog
Chow and was injected intravenously with 1-2 mg/kg lasix
per day for 3-6 weeks until blood samples determined the
*

serum K to be maintained at
one week.

3-25 meq/1 or less for at least

The control procedure was then carried out.
>

C.

DIALYSIS

In addition to being fed trace potassium food,

four

dogs in group 4 and two dogs in group 5 were dialyzed one to
two times to speed the formation of the hypokalemic state.
These dogs were dialyzed on a travenol machine against a
bath with Diasol without potassium, but with physiologic
concentrations of calcium, magnesium,
phosphate,

etc.,

sodium,

chloride,

for 30 to 45 minutes, via jugular venous

and carotid arterial lines placed by sterile means and trans¬
iently for the dialysis.

All dogs were allowed to stabilize

for at least two days prior to their use in the preparation,
with their serum potassiums measured immediately prior to
surgery to ensure the continuance of the hypokalemic state.

D.

ANALYSIS OF HEART TISSUE POTASSIUM CONTENT

Two to three samples of 0.5 gram pieces of left ven¬
tricle from 13 animals

(groups 1,4 and5) were each weighed,
-31-
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dried for three days in a 100°C oven and reweighed.

Each

sample was dissolved in concentrated nitric acid for three
days,

then heated for ten minutes on a heating plate,

diluted up to a 10 ml total volume with water,

filtered

through glass wool and then analyzed for K and Na concentra¬
tion on an I.L.

flame photometer.

VI.

RESULTS

A.

All Groups

Carotid blood pressure and heart rate remained
relatively constant throughout each study once the surgical
preparation was completed and the animal allowed to stabilize
for at least

30 minutes.

Both the arrythmias and subsequent

decrease in blood pressure occasionally

occuring during the

placement of the coronary sinus catheter were transient with
a spontaneous return to the previous blood pressure, heart
rate and EKG with the coronary sinus catheter securely in
place.

The hypokalemic dogs

(groups

4 and 5) were found to

have a higher blood pressure throughout
225/150 and 190/1^5,

(with means of

respectively) than the three other

groups with a normal serum potassium (with means of 115/89,
120/100,

B.

and 170/145,

respectively).

Left Ventricular Tissue Uptake of Thallium-201

In the control group of 10 dogs,

thallium-201 left

ventricular myocardial tissue concentration
0.0453 - 0.0011

%

injected dose/gram,

(- SEM)

(see Table I;

averaged
Figure 1,2)

In the 9 dogs studied during the peak effect of acute
intravenous furosemide

(2mg/kg) at 30 minutes post injection.

Group 2, myocardial thallium-201 uDtake
- 0.0023

%

(- SEM) was 0.0459

injected dose which did not significantly differ

■from control.
Similarly,

in the 7 dogs treated chronically with

intravenous furosemide over 9 days,
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in the absence of hypoka-

-

lemia.

Group 3,

no significant alteration in thallium-201

myocardial uptake was noted with a mean myocardial tissue
uptake of 0.050^6 - 0.0031

%

injected dose/gram.

In the 6 dogs rendered hypokalemic with serum potassium
going from 5-13 down to 2.95 meq/1 after 3 to 6 weeks on a
low potassium diet with or without dialysis,
myocardial thallium-201 concentration
from control to 0.0413 - 0.0035

%

Groun 4, mean

(- SEM)

fell hy 8.Rq$

injected dose/gram.

This

change in tissue thallium uptake did not significantly
differ from the control,

acute or chronic furosemide

(eukale-

i

mic) means.

See Figure 1.

However,

in the 7 dogs rendered hypokalemic with serum

potassium going from 5.21 down to 3-098 meq/1 with chronic
intravenous furosemide daily and a low potassium diet over
a 3 to 6 week period,with or without dialysis,
myocardial thallium-201 concentration
to 0.0361 - 0.0022

%

fell hy 20.31

%

injected dose/gram (p<0.01 between

this group and control,
groups.).

(- SEM)

Groun 5,

acute furosemide and chronic eukalemic

The results obtained with the hynokalemic dogs

were consistent within each group whether or not the dogs were
rendered hypokalemic with diet alone or with diet and dialysis.

C.

(A-V)

Differences

(see Table II;

(Carotid Artery - Coronary Sinus Blood)

figure 3 )

Myocardial thallium-201 uptake kinetics as judged by
A-V differences paralleled the tissue uptake with no signifi¬
cant differences between the control,

acute furosemide and

eukalemic chronic furosemide groups.

However,
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the hynokalemic-

no furosemide group.

Group 4, had the lowest

(A-V) difference

and therefore a decrease in myocardial thallium-201 uptake
compared to all other groups from sample 4

(one and three-

quarter minutes after the thallium injection)

to the last

sample at four minutes post thallium injection,
as compared with control
acute furosemide
osemide

in particular

(p<between 0.02 and 0.01), with

(p< 0.05-0.01), with eukalemic chronic fur¬

(p( between 0.05 and 0.01) and with chronic hypoka"j

lemic chronic furosemide

(p^ 0.05) •

In the chronic hypo¬

kalemic chronic furosemide group which statistically differed
i

from control,

acute

and eukalemic chronic furosemide,

myocardial tissue concentration of thallium-201, the

in

(A-V)

differences and therefore the thallium uptake was statistically
different from the other groups only in scattered samples,
(three to four minutes post thallium injection)
(two and one half minutes to four minutes)
furosemide,

(one and one half,

D.

versus acute

and three to four minutes)

versus eukalemic chronic furosemide,
minutes)

versus control,

and

(between one to two

versus hypokalemic-no furosemide group.

Potassium Concentration in Left Ventricular Myocardium

The three groups compared showed no significant change
in the potassium content in the myocardium of the hypokalemic
versus control animals.

The control had a mean of 8.0873

-0.1739 meq/wet tissue;

the hypokalemic-no furosemide animals

had a mean of 8.2339 -0.1324 meq/wet tissue and the chronic
furosemide-hypokalemic animals had a mean of 8.II65
meq/wet tissue.
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0.1718

VII.

DISCUSSION

It was the aim of this study to see if the administra¬
tion of the potent diuretic,

furosemide,

commonly used

clinically under both acute and chronic situations, would
effect the uptake of an ion commonly used as a tracer in
cardiac scanning, thallium-201.

Since our results showed no

alteration from control in thallium -201 uptake and in(A-V)
difference in the acute and chronic normo-kalemic situation,
we decided to pursue this investigation using chronic furose¬
mide under a hypokalemic environment, which is a common
occurrence in the clinical situation.

Since our results

showed both a significant decrease in tissue

(left ventricle)

uptake of thallium-201 and a decreased

difference in

(A-V)

CPM/cc/mCi with this group, we wondered if this decreased
uptake was due to the hypokalemia alone.

We therefore conducted

a control for this situation and tested dogs made hypokalemic
via diet alone or diet plus dialysis and no furosemide.
These latter results were inconclusive for tissue thallium201 uptake since they demonstrated a trend toward values
lower than the control,
kalemic dogs,

acute and chronic furosemide-normo-

and higher than the one group that differed

significantly from control,
group.
group

Group 5.
,

Group 4,

the hypokalemic chronic furosemide

Therefore this hypokalemic-no furosemide
approached but did not achieve statistical

significance from any other group.

More studies,

currently

under way, will be needed to resolve whether this group with
hypokalemia alone, will stand as a group by itself, will
merge with the control group,
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or will merge with the one

significantly different group with decreased thallium-201
uptake,

the hypokalemic,

chronic furosemide group.

last possibility comes about,

If the

it could be interpreted as

meaning that it was the hypokalemic environment and not the
furosemide which most likely caused the decrease in myocar¬
dial thallium-201 uptake.
group,

If it trends toward the control

it would seem likely that a possible interpretation

would be that both a hypokalemic environment along with the
chronic administration of furosemide is needed to effect the
cationic balance and enzyme systems enough to result in a
decreased uptake of thallium-201 by the heart.
more studies,

it stands as a group by itself,

significantly different

If, with
and becomes

from and in between both the control

and hypokalemic,chronic furosemide groups,

it would lend itself

to the interpretation that several factors, each contributing
to the whole,

influence thallium-201 uptake by the heart,

the more of these factors
etc.)

(hypokalemia,

are on board in the environment,

and

chronic furosemide,
the less thallium-201

uptake will occur.
Of considerable interest are the

(A-V)

difference

results of the various, with the hypokalemic only groun
showing a significantly smaller (A-V) difference,
the smallest uptake of thallium-201,
including the hypokalemic,

indicating

than every other group

chronic furosemide group

although only in scattereu samples.

(GrouD 4)

(Group 5)

This would indicate that

these future studies will probably result in the hypokalemic
group

(Group 4)

either standing on its own or merging with

the hypokalemic chronic furosemide with the above interpretations
aPplicable.
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Although the biochemical mechanisms governing
thallium-201 uptake,

along with how various environmental

factors may alter this uptake, have not as yet been resolved,
some interpretation of how studies presented earlier in this
paper, may be relevant to the results of this study will
be attempted.
It has been shown by numerous investigators that an
environment with low external serum potassium (hypokalemia)
results in a decreased uptake of Na+ and K+ by kidney tubules
and red blood cells

(32,39,40,41,42).

Since thallium-201

has been shown to act as potassium in vivo

(1,2,8,9)

it would

not be unexpected to get a decrease in tissue uptake of
thallium-201 in a hypokalemic environment.

In addition,

studies have shown furosemide to inhibit cation co-transport
and block uptake of Na+ and K+ in various tissues
cells,

renal tubules,

(red blood

salivary duct epithelium)(7,31,32,3Q,40).

To further support the idea that furosemide directly
inhibits potassium uptake by the heart.

Seller in 1975

(7)

found that furosemide significantly increased the digitalis
induced myocardial loss of potassium (as measured by increased
coronary sinus-femoral artery potassium difference).
Thus furosemide may act synergistically with the
hypokalemia and lead to a decrease in thallium-201 uptake
by the heart.
If furosemide inhibits myocardial potassium uptake as
the studies seem to show,

one may wonder why the acute and

chronic administration of furosemide without hypokalemia
did not lead to a decreased tissue uptake of thallium-201 or

-38-
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a decrease in

(A-V)

difference.

One may speculate that a

higher serum concentration of furosemide might be needed to
see an effect and/or that the normal to high serum potassium
of 5.1 in the non-hypokalemic animals may have overridden
the effect that might be seen with furosemide alone.

The

chronic furosemide together with low serum potassium would,
leave no opposing force to the furosemide?s inhibition to
potassium,

or in this case,

thallium-201 uptake.

It is possible that with the cardiac tissue retaining
its potassium content, while the serum and skeletal muscles
show concomitant reductions in potassium, when made chronically
potassium deficient via diet,
(59),

and Cameron in 1975

as shown by Poole-Wilson in 1Q75

(6l), and this study,

that the

potassium deficient serum and skeletal muscles may act as a
sink for the bolus of thallium-201 injected,

thus leading to

decreased myocardial uptake of this ion, with none of the
projected effects on enzyme systems actually occurring as
speculated above.
Since the localization of an infarct with thallium-201
imaging agent is dependent on the lack of perfusion to the
infarcted area with a subsequent lack of thallium—201 uptake
in that area and thereby the visualization of a "cold spot",
the occurrence of a decreased uptake of thallium-201 into
normal myocardium under various conditions

(hypokalemia and

furosemide) would obscure the differences from the abnormal
zones under these conditions.
In addition to the finding that acutely reduced serum
potassium leads to reduced potassium uptake by kidney tubules
and erythrocytes,

Erdman in 1971
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(62)

and Bluschke in 1976(61)

"

found that 12 days of hypokalemia from diet significantly
enhanced the activity of cardiac Na+,K+-ATPase which would
presumably lead to an increased myocardial potassium uptake
whereas this ATPase of the kidney and brain showed no signi¬
ficant change in activity from controls.

The same result

was found with 14 days of subcutaneous digoxin
an inhibitor of this ATPase.

(0.3 mg/kg),

As the activity of the Na+,K+-

ATPase is dependent on the potassium concentration and as
cardiac glycosides are the specific inhibitors of this
enzyme,

the observed increase in activity may be explained

by an adaptive reponse to the inhibition of the ATPase

(6l).

This increased ATPase activity would presumably return the
myocardial potassium uptake toward normal in the face of its
inhibitors

(hypokalemia and/or digoxin).

To relate these findings to the present study,
possible that the hypokalemic alone group,

it is

Grouo 4, had

increased cardiac Na+,K+-ATPase activity due to the chronic
hypokalemia which in turn prevented the expected decrease
in thallium-201 uptake
serum potassium).

(also due to the decrease in external

It is possible that this group's intermediate

mean value for tissue uptake of thallium-201 was due to
these opposing factors.
furosemide group.

In the chronic hypokalemic chronic

Group 5, this possible increase in ATPase

activity may have been inhibited by the action of the furose¬
mide leading to the significant reduction in myocardial uptake
of thallium-201.

If this was so though, one must question

why the chronic furosemide alone did not result in an even
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greater reduction of uptake.
to whether furosemide

One might also speculate as

(itself an ATPase inhibitor) might

also lead to an increase in the activity of this ATPase if
given chronically,

as did the digoxin.

In the view of this author and Seller

(7),

it is

more probable that the furosemide and hypokalemia may more
directly effect the sites where the potassium and thallium201 act on the myocardium than the above study on the
induction of the Na+,K+-ATPase.
From this present study,

it is possible to make

i

several inferences on how the information gained may be
useful in the clinical situation when quantifying thallium201 scans or looking for relative differences between scans.
Let us suppose that a patient is admitted with a diagnosis
of acute myocardial infarction or is to have an myocardial
infarction ruled out,

and it is decided that a thallium-201

scan would be an appropriate tool in his management,

it

would be most important in the quantitative interpretation
of that and subsequent scans to know if he is currently
hypokalemic and/or taking medications such as furodemide,
a long term basis or even acutely.

on

From this study, we

would expect his scanning results to be the same as control
as long as the patient has a normal serum potassium,no
matter what his history of taking furosemide.

If he has been

chronically on furosemide and is hypokalemic alone, then the
uptake of the myocardial thallium-201 will be influenced.
If normal myocardial tissue is influenced by these various
environments to have a decrease in thallium-201 uptake then

-

the contrast between normal and abnormal regions will be de¬
creased resulting in an inability to detect a lesion or the
attenuation of the results.
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*0^

per gram
201T1

.03 -

Uptake in
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--

.01

--
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9

7

(3)

(4)
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6

(5)
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Decrease in thallium-201 Uptake in Canine Free
Left Ventricle under control, acute and chronic
furosemide and under normal and hypokalemic
conditions.
The numbers in the lower part of
each column represents the number of experiments
of each kind.
The number in the parenthesis is
the group number.
p < 0. 01

(1)

=

control

(2)

=

acute furosemide

(3)

=

chronic furosemide

(4)

=

hypokalemia alone

(5)

=

hypokalemia and furosemide
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